Gut microbiota and liver diseases

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1691-1702

  Minemura, Masami ^a   Shimizu, Yukihiro ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Nanto Municipal Hospital   (Japan)

Author keywords

Gut microbiota; Hepatic encephalopathy; Immune system; Liver disease; Metabolites; Non alcoholic fatty liver disease

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CD1D ANTIGEN; LACTULOSE; PREBIOTIC AGENT; PROBIOTIC AGENT; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL TRANSLOCATION; BACTEROIDACEAE; BIFIDOBACTERIUM; CLOSTRIDIUM; ENTEROBACTERIACEAE; ENTEROCOCCUS; EUBACTERIUM; FUSOBACTERIUM; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; LACTOBACILLUS; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER DISEASE; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PEPTOSTREPTOCOCCUS; PREVOTELLACEAE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; STAPHYLOCOCCUS; STREPTOCOCCUS; TH17 CELL; VEILLONELLA; ANIMAL; BACTERIUM; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INTESTINE; LIVER; LIVER DISEASES; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BACTERIA; BACTERIAL TRANSLOCATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; LIVER; LIVER DISEASES; MICROBIOTA; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84922756566     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1691     Document Type: Article

References (108)

1. Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 2000; 26: 95-111 [PMID: 10941602]
2. Patrignani P, Tacconelli S, Bruno A. Gut microbiota, host gene expression, and aging. J Clin Gastroenterol 2014; 48 Suppl 1: S28-S31 [PMID: 25291121]
3. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. Front Microbiol 2014; 5: 494 [PMID: 25295033 DOI: 10.3389/fmicb.2014.00494]
4. Neish AS. Mucosal immunity and the microbiome. Ann Am Thorac Soc 2014; 11 Suppl 1: S28-S32 [PMID: 24437401]
5. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 2012; 149: 1578-1593 [PMID: 22726443 DOI: 10.1016/j.cell.2012.04.037]
6. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13: 321-335 [PMID: 23618829 DOI: 10.1038/nri3430]
7. Spasova DS, Surh CD. Blowing on embers: commensal microbiota and our immune system. Front Immunol 2014; 5: 318 [PMID: 25120539 DOI: 10.3389/fimmu.2014.00318]
8. Quigley EM, Monsour HP. The gut microbiota and the liver: implications for clinical practice. Expert Rev Gastroenterol Hepatol 2013; 7: 723-732 [PMID: 24134195 DOI: 10.1586/17474124.2013.848167]
9. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59: 328-339 [PMID: 23703735 DOI: 10.1002/hep.26494]
10. Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014; 29: 1139-1148 [PMID: 24547986 DOI: 10.1111/jgh.12556]
11. Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013; 16: 576-581 [PMID: 23873346 DOI: 10.1097/MCO.0b013e32836410a4]
12. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
13. Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E 4th, Taylor CM, Welsh DA, Berthoud HR. Obese-type Gut Microbiota Induce Neurobehavioral Changes in the Absence of Obesity. Biol Psychiatry 2014; Epub ahead of print [PMID: 25173628]
14. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 2014; 20: 8859-8866 [PMID: 25083059]
15. O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 2015; 277: 32-48 [PMID: 25078296]
16. Lagier JC, Million M, Hugon P, Armougom F, Raoult D. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol 2012; 2: 136 [PMID: 23130351 DOI: 10.3389/fcimb.2012.00136]
17. Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr) 2012; 34: 247-267 [PMID: 21347607 DOI: 10.1007/s11357-011-9217-5]
18. Petrosino JF, Highlander S, Luna RA, Gibbs RA, Versalovic J. Metagenomic pyrosequencing and microbial identification. Clin Chem 2009; 55: 856-866 [PMID: 19264858 DOI: 10.1373/clinchem.2008.107565]
19. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4586-4591 [PMID: 20571116]
20. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002; 51: 448-454 [PMID: 11990498]
21. Woodmansey EJ. Intestinal bacteria and ageing. J Appl Microbiol 2007; 102: 1178-1186 [PMID: 17448153 DOI: 10.1111/j.1365-2672.2007.03400.x]
22. Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol 2004; 70: 6113-6122 [PMID: 15466557 DOI: 10.1128/AEM.70.10.6113-6122.2004]
23. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990; 70: 567-590 [PMID: 2181501]
24. Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm 2014; 2014: 162021 [PMID: 25214711]
25. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81: 1031-1064 [PMID: 11427691]
26. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-1286 [PMID: 19865172 DOI: 10.1038/nature08530]
27. Sina C, Gavrilova O, Förster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, Rehmann A, Franke A, Ott S, Häsler R, Nikolaus S, Fölsch UR, Rose-John S, Jiang HP, Li J, Schreiber S, Rosenstiel P. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 2009; 183: 7514-7522 [PMID: 19917676 DOI: 10.4049/jimmunol.0900063]
28. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012; 148: 1258-1270 [PMID: 22424233 DOI: 10.1016/j.cell.2012.01.035]
29. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010; 107: 12204-12209 [PMID: 20566854 DOI: 10.1073/pnas.0909122107]
30. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-341 [PMID: 21205640 DOI: 10.1126/science.1198469]
31. Zeissig S, Blumberg RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system. FEBS Lett 2014; 588: 4188-4194 [PMID: 24983499]
32. Olszak T, Neves JF, Dowds CM, Baker K, Glickman J, Davidson NO, Lin CS, Jobin C, Brand S, Sotlar K, Wada K, Katayama K, Nakajima A, Mizuguchi H, Kawasaki K, Nagata K, Müller W, Snapper SB, Schreiber S, Kaser A, Zeissig S, Blumberg RS. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 2014; 509: 497-502 [PMID: 24717441 DOI: 10.1038/nature13150]
33. Ferreira CM, Vieira AT, Vinolo MA, Oliveira FA, Curi R, Martins Fdos S. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res 2014; 2014: 689492 [PMID: 25309932]
34. Hansen CH, Nielsen DS, Kverka M, Zakostelska Z, Klimesova K, Hudcovic T, Tlaskalova-Hogenova H, Hansen AK. Patterns of early gut colonization shape future immune responses of the host. PLoS One 2012; 7: e34043 [PMID: 22479515 DOI: 10.1371/journal.pone.0034043]
35. Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe 2012; 12: 496-508 [PMID: 23084918 DOI: 10.1016/j.chom.2012.09.009]
36. Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012; 18: 337-346 [PMID: 23323248 DOI: 10.3350/cmh.2012.18.4.337]
37. Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58: 1020-1027 [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023]
38. Clarke SF, Murphy EF, Nilaweera K, Ross PR, Shanahan F, O'Toole PW, Cotter PD. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes 2012; 3: 186-202 [PMID: 22572830 DOI: 10.4161/gmic.20168]
39. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845]
40. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]
41. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, Mawatari H, Shibata W, Kitani H, Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012; 16: 44-54 [PMID: 22768838 DOI: 10.1016/j.cmet.2012.05.012]
42. Miettinen TA. Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease. Gut 1972; 13: 682-689 [PMID: 4118161 DOI: 10.1136/gut.13.9.682]
43. Sung JY, Shaffer EA, Costerton JW. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Dig Dis Sci 1993; 38: 2104-2112 [PMID: 8223087 DOI: 10.1007/BF01297092]
44. Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, Stotzer PO, Abrahamsson H, Olsson R, Björnsson ES. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003; 98: 1362-1370 [PMID: 12818282 DOI: 10.1111/j.1572-0241.2003.07475.x]
45. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-572 [PMID: 21574172 DOI: 10.1002/hep.24423]
46. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011; 61: 693-703 [PMID: 21286703 DOI: 10.1007/s00248-010-9801-8]
47. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, Xu W, Ehrlich SD, Zheng S, Li L. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513: 59-64 [PMID: 25079328 DOI: 10.1038/nature13568]
48. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105 [PMID: 21254165 DOI: 10.1002/hep.24018]
49. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966-G978 [PMID: 22241860 DOI: 10.1152/ajpgi.00380.2011]
50. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-169 [PMID: 2050995 DOI: 10.1016/0168-8278(91)90933-3]
51. Rivera CA, Bradford BU, Seabra V, Thurman RG. Role of endotoxin in the hypermetabolic state after acute ethanol exposure. Am J Physiol 1998; 275: G1252-G1258 [PMID: 9843760]
52. Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 2013; 28 Suppl 1: 38-42 [PMID: 23855294]
53. Tuomisto S, Pessi T, Collin P, Vuento R, Aittoniemi J, Karhunen PJ. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 2014; 14: 40 [PMID: 24564202 DOI: 10.1186/1471-230X-14-40]
54. Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-G175 [PMID: 21940902 DOI: 10.1152/ajpgi.00190.2011]
55. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303: G675-G685 [PMID: 22821944 DOI: 10.1152/ajpgi.00152.2012]
56. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101 [PMID: 23803760 DOI: 10.1038/nature12347]
57. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516 [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007]
58. Bindels LB, Porporato P, Dewulf EM, Verrax J, Neyrinck AM, Martin JC, Scott KP, Buc Calderon P, Feron O, Muccioli GG, Sonveaux P, Cani PD, Delzenne NM. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 2012; 107: 1337-1344 [PMID: 22976799 DOI: 10.1038/bjc.2012.409]
59. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-989 [PMID: 19329213 DOI: 10.1016/j.jhep.2008.12.033]
60. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627 [PMID: 12411307 DOI: 10.1182/blood-2002-05-1461]
61. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498 [PMID: 19836068 DOI: 10.1016/j.cell.2009.09.033]
62. Ersöz G, Aydin A, Erdem S, Yüksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 409-412 [PMID: 10321758 DOI: 10.1097/00042737-199904000-00009]
63. Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012; 16: 301-320 [PMID: 22541700 DOI: 10.1016/j.cld.2012.03.009]
64. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-1165 [PMID: 18628377 DOI: 10.1136/gut.2007.122176]
65. Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol 2009; 15: 1042-1049 [PMID: 19266595 DOI: 10.3748/wjg.15.1042]
66. Lata J, Stiburek O, Kopacova M. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol 2009; 15: 5505-5510 [PMID: 19938187 DOI: 10.3748/wjg.15.5505]
67. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066 [PMID: 15277442 DOI: 10.2337/diacare.27.8.2057]
68. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]
69. Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987; 15: 335-343 [PMID: 3125077]
70. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 39-46 [PMID: 8530808 DOI: 10.1016/0168-8278(95)80309-2]
71. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449 [PMID: 15122774 DOI: 10.1002/hep.20194]
72. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52: 3259-3265 [PMID: 17393330 DOI: 10.1007/s10620-006-9687-y]
73. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715 [PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x]
74. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20: 506-511 [PMID: 18467909 DOI: 10.1097/MEG.0b013e3282f3e6f5]
75. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011; 23: 725-732 [PMID: 21646910 DOI: 10.1097/MEG.0b013e32834696f5]
76. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206 [PMID: 19730107 DOI: 10.1097/MEG.0b013e328330a8d3]
77. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay- Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011; 27: 177-181 [PMID: 20452184 DOI: 10.1016/j.nut.2010.01.006]
78. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011; (11): CD008716 [PMID: 22071855]
79. Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012; 42: 1008-1015 [PMID: 22548675 DOI: 10.1111/j.1872-034X.2012.01015.x]
80. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107: 1043-1050 [PMID: 22710579 DOI: 10.1038/ajg.2012.113]
81. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8.e1 [PMID: 24246768]
82. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39: 1113-1125 [PMID: 24628464 DOI: 10.1111/apt.12695]
83. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 [PMID: 7382552]
84. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193]
85. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
86. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587-596 [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1]
87. Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004; 20: 146-155 [PMID: 15703637 DOI: 10.1097/00001574-200403000-00017]
88. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350 [PMID: 12540784 DOI: 10.1053/jhep.2003.50048]
89. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-997 [PMID: 19115316 DOI: 10.1002/hep.22711]
90. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-1095 [PMID: 22013734]
91. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
92. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
93. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-262 [PMID: 23396737]
94. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911]
95. Tannock GW, Wilson CM, Loach D, Cook GM, Eason J, O'Toole PW, Holtrop G, Lawley B. Resource partitioning in relation to cohabitation of Lactobacillus species in the mouse forestomach. ISME J 2012; 6: 927-938 [PMID: 22094343 DOI: 10.1038/ismej.2011.161]
96. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108: 975-982 [PMID: 7698613 DOI: 10.1016/0016-5085(95)90192-2]
97. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-951 [PMID: 18433921 DOI: 10.1016/j.jhep.2008.02.015]
98. Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int J Food Microbiol 2008; 128: 371-377 [PMID: 18976829 DOI: 10.1016/j.ijfoodmicro.2008.09.023]
99. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682 [PMID: 19038698 DOI: 10.1016/j.alcohol.2008.08.006]
100. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009; 43: 163-172 [PMID: 19251117 DOI: 10.1016/j.alcohol.2008.12.009]
101. Arora S, Kaur IP, Chopra K, Rishi P. Efficiency of double layered microencapsulated probiotic to modulate proinflammatory molecular markers for the management of alcoholic liver disease. Mediators Inflamm 2014; 2014: 715130 [PMID: 24966470]
102. Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol 2012; 303: G32-G41 [PMID: 22538402 DOI: 10.1152/ajpgi.00024.2012]
103. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665 [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183]
104. El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, Juvonen RO, Salminen SJ, Poussa T, Mykkänen HM. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr 2006; 83: 1199-1203 [PMID: 16685066]
105. 1-induced hepatocellular carcinoma. Gene 2011; 490: 54-59 [PMID: 21963996 DOI: 10.1016/j.gene.2011.09.003]
106. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am J Transplant 2005; 5: 125-130 [PMID: 15636620 DOI: 10.1111/j.1600-6143.2004.00649.x]
107. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg 2011; 201: 498-502 [PMID: 20619394 DOI: 10.1016/j.amjsurg.2010.02.013]
108. Rifatbegovic Z, Mesic D, Ljuca F, Zildzic M, Avdagic M, Grbic K, Agic M, Hadziefendic B. Effect of probiotics on liver function after surgery resection for malignancy in the liver cirrhotic. Med Arh 2010; 64: 208-211 [PMID: 21246916]